一图读懂康哲药业（00867）2024全年业绩：重塑与突破，“新康哲”开启创新“新征程”
2025年3月17日，康哲药业(00867)发布2024全年业绩，因受到国采执行影响，2024年全年实现营收74.69亿元，同比下降6.8%;若全按药品销售收入计算，营收为86.22亿元，同比下降9.0%。公司剔除相关资产减值损失计提后的正常化净利润为17.14亿元。
对于公司而言，2024年既是挑战中的“重塑之年”，更是光芒初现的“突破之年”。公司整体业绩虽正经历短期阵痛，但独家药、创新药发展却不乏亮点，潜力已初步显现。公司2024年全按药品销售收入计算的独家产品及创新产品营收达45.51亿元，占总营业额的比重达到52.8%。2024年，公司递交了重磅白癜风治疗创新药芦可替尼乳膏等2款新药的中国NDA，新增3项创新合作、3款医美产品合作。目前，公司已储备的短、中、长期创新管线总计近40项，累计5款创新药进入商业化。未来随着已上市创新药逐步铺开大规模临床应用与放量，以及储备优质创新管线源源不断获批上市，康哲药业将进入由独家药、创新药驱动的高质量、可持续发展新周期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10